* 2012 Third-Quarter Non-GAAP EPS Increased to $0.95, Excluding Certain Items; GAAP EPS of $0.56
* Worldwide Sales of $11.5 Billion, a Decrease of 4 Percent; Comparable to Third-Quarter 2011 Sales, Excluding the Unfavorable Impact of Foreign Exchange
* Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS, ZOSTAVAX and ISENTRESS; Offset by the Decline in SINGULAIR Sales Following Patent Expiry in the United States
* Anticipates Multiple New Product Submissions in 2012-2013, Including Suvorexant and Odanacatib
* Narrows 2012 Full-Year Non-GAAP EPS Target to $3.78 to $3.82, Excluding Certain Items; GAAP EPS Range of $2.08 to $2.24
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2012.
* Worldwide Sales of $11.5 Billion, a Decrease of 4 Percent; Comparable to Third-Quarter 2011 Sales, Excluding the Unfavorable Impact of Foreign Exchange
* Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS, ZOSTAVAX and ISENTRESS; Offset by the Decline in SINGULAIR Sales Following Patent Expiry in the United States
* Anticipates Multiple New Product Submissions in 2012-2013, Including Suvorexant and Odanacatib
* Narrows 2012 Full-Year Non-GAAP EPS Target to $3.78 to $3.82, Excluding Certain Items; GAAP EPS Range of $2.08 to $2.24
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2012.
